VERU Stock — Veru Inc.: Cash, EV, Pipeline

Share price

$2.41

Market cap

$41.1M

Cash

$23.9M

Enterprise value

$17.2M

Balance sheet

Cash	$23.9M
Debt	$0.0M
Net cash	$23.9M
Enterprise value	$17.2M
Basic shares	17.1M shares
Fully diluted shares	45.5M shares
Fully diluted market cap	$109.7M
Cash per share	$1.40

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VERU daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	Enobosarm	Phase 2	Obesity & Overweight; Mobility Disability; HOMA-IR	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Enobosarm

Phase 2 · Active Modality: oral selective androgen receptor modulator (SARM)

Target androgen receptor

Partnerships Novo Nordisk (clinical supply agreement for Wegovy, June 2026)

Indications

obesity (augment fat loss and preserve muscle with GLP-1 RA therapy) (Phase 2)

Status note PLATEAU Phase 2b ongoing with Wegovy; QUALITY Phase 2b completed.

Sabizabulin

Preclinical · Active Modality: oral broad anti-inflammatory agent

Target microtubules

Indications

atherosclerotic cardiovascular disease (Preclinical)

Status note Planned Phase 2 for inflammation in atherosclerotic cardiovascular disease; no active new-indication trial per filing.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Enobosarm
Lead indication	Obesity & Overweight
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07446998	Phase 2	Active, not recruiting	Sponsor	VERU	—	Obesity & Overweight; Mobility Disability; HOMA-IR	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Veru Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	35,000	no change	0.01%	2026-08-14
Ikarian Capital	0	-133,517	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VERU — Veru Inc.